Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Vincenzo Accurso MD, Marco Santoro MD, Salvatrice Mancuso MD, Marisante Napolitano MD, Florinda Di Piazza MD, Antonio Russo MD, Sergio Mario Siragusa MD

Article Type

Case Report

Published

This case report presents initial experience with a patient affected by primary myelofibrosis, retreated with ruxolitinib after a 3-month suspension of
therapy due to clinical decision.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.